Literature DB >> 12441067

Transduction of umbilical cord blood CD34+ NOD/SCID-repopulating cells by simian foamy virus type 1 (SFV-1) vector.

James R Zucali1, Tina Ciccarone, Vicky Kelley, Jeonghae Park, Calvin M Johnson, Ayalew Mergia.   

Abstract

Foamy viruses are nonpathogenic retroviruses that offer unique opportunities for gene transfer into various cell types including hematopoietic stem cells. We used a simian foamy virus type 1 vector (SFV-1) containing a LacZ reporter gene with a titer of 1-5 x 10(6) viral particles/ml that was free of replication-competent retrovirus to transduce human umbilical cord blood CD34+ cells. Transduced CD34+ cord blood cells were transplanted into NOD/SCID mice and plated in serum-free methylcellulose culture to determine the transduction efficiency of human hematopoietic progenitor cells. A transduction efficiency of about 20% was obtained. At 6-10 weeks posttransplantation, human hematopoietic cell engraftment and marking were determined. Marrow from transplanted mice demonstrated human cell engraftment by the presence of human (CD45+) cells containing both CD19+ lymphoid and CD33+ myeloid cells. Serial sampling of NOD/SCID bone marrow revealed the presence of 6.7-14.0% CD45+ cells at 6 weeks posttransplant as compared to 3.6-27.2% CD45+ cells at 9-10 weeks posttransplant. Human progenitors examined from NOD/SCID bone marrow cells 9 weeks posttransplant revealed from 7.4 to 25.9% of the colonies exhibiting X-gal staining. Our study demonstrates the ability of a simian foamy virus vector to transduce the SCID-repopulating cell and offers a promising new gene delivery system for use in hematopoietic stem cell gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441067     DOI: 10.1006/viro.2002.1604

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors.

Authors:  Grant Trobridge; David W Russell
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Foamy virus vector integration sites in normal human cells.

Authors:  Grant D Trobridge; Daniel G Miller; Michael A Jacobs; James M Allen; Hans-Peter Kiem; Rajinder Kaul; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-20       Impact factor: 11.205

3.  A Kaposi's sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rγnull mice.

Authors:  Isaac W Boss; Peter E Nadeau; Jeffrey R Abbott; Yajie Yang; Ayalew Mergia; Rolf Renne
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.

Authors:  T R Bauer; E M Olson; Y Huo; L M Tuschong; J M Allen; Y Li; T H Burkholder; D W Russell
Journal:  Gene Ther       Date:  2011-01-13       Impact factor: 5.250

5.  Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells.

Authors:  Yue Si; Anna C Pulliam; Yvonne Linka; Samantha Ciccone; Cordula Leurs; Jin Yuan; Olaf Eckermann; Stefan Fruehauf; Sean Mooney; Helmut Hanenberg; D Wade Clapp
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

6.  Activity of TAR in inducible inhibition of HIV replication by foamy virus vector expressing siRNAs under the control of HIV LTR.

Authors:  Jeonghae Park; Peter E Nadeau; Ayalew Mergia
Journal:  Virus Res       Date:  2009-01-09       Impact factor: 3.303

Review 7.  Foamy virus vectors for gene transfer.

Authors:  Grant D Trobridge
Journal:  Expert Opin Biol Ther       Date:  2009-11       Impact factor: 4.388

8.  The foamy virus genome remains unintegrated in the nuclei of G1/S phase-arrested cells, and integrase is critical for preintegration complex transport into the nucleus.

Authors:  Yung-Tsun Lo; Tao Tian; Peter E Nadeau; Jeonghae Park; Ayalew Mergia
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

Review 9.  Foamy virus vectors for HIV gene therapy.

Authors:  Miles E Olszko; Grant D Trobridge
Journal:  Viruses       Date:  2013-10-22       Impact factor: 5.048

Review 10.  Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.

Authors:  Arun K Nalla; Grant D Trobridge
Journal:  Biomedicines       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.